219 related articles for article (PubMed ID: 35069219)
1. Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma.
Lapidot M; Saladi SV; Salgia R; Sattler M
Front Pharmacol; 2021; 12():806570. PubMed ID: 35069219
[TBL] [Abstract][Full Text] [Related]
2. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
3. Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma.
Wadowski B; Bueno R; De Rienzo A
Front Oncol; 2021; 11():684025. PubMed ID: 34178677
[TBL] [Abstract][Full Text] [Related]
4. Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma.
Al Khatib MO; Pinton G; Moro L; Porta C
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900330
[TBL] [Abstract][Full Text] [Related]
5. LncRNAs and related molecular basis in malignant pleural mesothelioma: Challenges and potential.
Xu X; Li H; Xie M; Zhou Z; Wang D; Mao W
Crit Rev Oncol Hematol; 2023 Jun; 186():104012. PubMed ID: 37116816
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.
Rovers S; Janssens A; Raskin J; Pauwels P; van Meerbeeck JP; Smits E; Marcq E
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327475
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors-Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment.
Yoshikawa Y; Kuribayashi K; Minami T; Ohmuraya M; Kijima T
Front Oncol; 2020; 10():554570. PubMed ID: 33381446
[TBL] [Abstract][Full Text] [Related]
8. Genomics and Functional Genomics of Malignant Pleural Mesothelioma.
Cakiroglu E; Senturk S
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882916
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
Thellung S; Favoni RE; Würth R; Nizzari M; Pattarozzi A; Daga A; Florio T; Barbieri F
Curr Drug Targets; 2016; 17(7):824-49. PubMed ID: 26240051
[TBL] [Abstract][Full Text] [Related]
10. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
11. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Lapidot M; Case AE; Weisberg EL; Meng C; Walker SR; Garg S; Ni W; Podar K; Hung YP; Carrasco RD; Knott A; Gokhale PC; Sharma S; Pozhitkov A; Kulkarni P; Frank DA; Salgia R; Griffin JD; Saladi SV; Bueno R; Sattler M
Br J Cancer; 2021 Aug; 125(4):582-592. PubMed ID: 34088988
[TBL] [Abstract][Full Text] [Related]
12. Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations.
Lorenzini E; Ciarrocchi A; Torricelli F
J Clin Med; 2021 Jun; 10(11):. PubMed ID: 34199544
[TBL] [Abstract][Full Text] [Related]
13. The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma.
Arulananda S; Lee EF; Fairlie WD; John T
Expert Rev Anticancer Ther; 2021 Apr; 21(4):413-424. PubMed ID: 33238762
[No Abstract] [Full Text] [Related]
14. Immunotherapy in malignant pleural mesothelioma: a review of literature data.
Menis J; Pasello G; Remon J
Transl Lung Cancer Res; 2021 Jun; 10(6):2988-3000. PubMed ID: 34295692
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM).
Lapidot M; Case AE; Larios D; Gandler HI; Meng C; Tošić I; Weisberg EL; Poitras MJ; Gokhale PC; Paweletz CP; Podar K; Salgia R; Saladi SV; Griffin JD; Frank DA; Bueno R; Sattler M
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374980
[TBL] [Abstract][Full Text] [Related]
16. An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.
Davis A; Ke H; Kao S; Pavlakis N
Lung Cancer (Auckl); 2022; 13():1-12. PubMed ID: 35264891
[TBL] [Abstract][Full Text] [Related]
17. A Narrative Review-Management of Malignant Pleural Effusion Related to Malignant Pleural Mesothelioma.
Qureshi M; Thapa B; Muruganandan S
Heart Lung Circ; 2023 May; 32(5):587-595. PubMed ID: 36925448
[TBL] [Abstract][Full Text] [Related]
18. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
Hegedüs L; Okumus Ö; Mairinger F; Ploenes T; Reuter S; Schuler M; Welt A; Vega-Rubin-de-Celis S; Theegarten D; Bankfalvi A; Aigner C; Hegedüs B
Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
Tolani B; Acevedo LA; Hoang NT; He B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
[TBL] [Abstract][Full Text] [Related]
20. Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms.
Cersosimo F; Barbarino M; Lonardi S; Vermi W; Giordano A; Bellan C; Giurisato E
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
